A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
AI tools overhype research findings far more often than humans, with a study suggesting the newest bots are the worst offenders—particularly when they are specifically instructed not to exaggerate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback